ArriVent BioPharma, Inc (AVBP) - Price to Earnings Ratio

Corporate emblem and logo of ArriVent Corp (AVBP)

ArriVent BioPharma, Inc (AVBP) share price action is tied to the stage of the biotechnological cycle, rendering the company's fundamental P/E independent of macroeconomics. Growth is based on the success of furmonertinib in treating NSCLC and the prospects of FDA approval, while therapy efficacy relies on strict drug distribution protocols. The value of -4.00 represents the current level of the indicator, allowing investors to assess the market liquidity premium of the asset.

ArriVent Corp (AVBP): Price to Earnings Ratio from 03/30/2024 to 11/14/2026

Comprehensive metric breakdowns and analytics for ArriVent BioPharma, Inc (AVBP)

- share price and expert price forecast:
Price Performance Chart ArriVent|AVBP - Analyst Consensus Forecast
- market capitalization indicators:
Market Valuation ArriVent BioPharma, Inc.|AVBP - Enterprise Value
- balance sheet equity data:
Book Value per Share ArriVent BioPharma|AVBP - Company Book Value|Capitalization to Book Value Ratio arrivent.com|AVBP - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio ArriVent BioPharma, Inc|AVBP - Long-Term Debt to Capital|Current Liabilities to Capital arrivent.com|AVBP - Company Debts|Debt to Net Assets Ratio ArriVent BioPharma, Inc.|AVBP - Company Long-Term Debts|Company Short-Term Debts ArriVent BioPharma|Intermediate Coverage Ratio arrivent.com
- net income and valuation ratios data:
AVBP - Company Net Income|Expected Net Income ArriVent BioPharma, Inc|AVBP - P/E Multiple|Market Cap to Projected Earnings ArriVent BioPharma Inc|AVBP - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ArriVent BioPharma, Inc.|AVBP - Operating profit EBITDA|Net earnings per one share for the last twelve months ArriVent BioPharma|AVBP - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months arrivent.com|AVBP - Net earnings per share growth this year|Projected earnings per share increase next year ArriVent BioPharma, Inc
- sales volume and revenue indicators:
AVBP - Company Sales|Company Future Revenue ArriVent BioPharma, Inc|AVBP - P/S Multiple|Price-to-Projected Revenue Ratio ArriVent BioPharma, Inc.
Comprehensive company analysis:ArriVent BioPharma, Inc. - AVBP
Signature product of ArriVent BioPharma Inc

The P/E ratio reflects the market value of a single unit of net profit, allowing for an assessment of the asset's premium in light of inflationary risks and the cost of capital. By analyzing the historical P/E chart of ArriVent BioPharma, Inc (AVBP), an investor can identify an entry point when the market undervalues the potential for scaling profits from lung cancer therapy patents with minimal operating expenses.

Key competitors

LTRN: Company Value to Net Income|P/E Multiple BIAF|Price to Earnings Ratio eEFFECTOR Therapeutics, Inc. EFTR